Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 85

1.

Frequent mutations of genes encoding ubiquitin-mediated proteolysis pathway components in clear cell renal cell carcinoma.

Guo G, Gui Y, Gao S, Tang A, Hu X, Huang Y, Jia W, Li Z, He M, Sun L, Song P, Sun X, Zhao X, Yang S, Liang C, Wan S, Zhou F, Chen C, Zhu J, Li X, Jian M, Zhou L, Ye R, Huang P, Chen J, Jiang T, Liu X, Wang Y, Zou J, Jiang Z, Wu R, Wu S, Fan F, Zhang Z, Liu L, Yang R, Liu X, Wu H, Yin W, Zhao X, Liu Y, Peng H, Jiang B, Feng Q, Li C, Xie J, Lu J, Kristiansen K, Li Y, Zhang X, Li S, Wang J, Yang H, Cai Z, Wang J.

Nat Genet. 2011 Dec 4;44(1):17-9. doi: 10.1038/ng.1014.

PMID:
22138691
2.

Targeting HIF2α translation with Tempol in VHL-deficient clear cell renal cell carcinoma.

Sourbier C, Srivastava G, Ghosh MC, Ghosh S, Yang Y, Gupta G, Degraff W, Krishna MC, Mitchell JB, Rouault TA, Linehan WM.

Oncotarget. 2012 Nov;3(11):1472-82.

3.

Mutation analysis of hypoxia-inducible factors HIF1A and HIF2A in renal cell carcinoma.

Morris MR, Hughes DJ, Tian YM, Ricketts CJ, Lau KW, Gentle D, Shuib S, Serrano-Fernandez P, Lubinski J, Wiesener MS, Pugh CW, Latif F, Ratcliffe PJ, Maher ER.

Anticancer Res. 2009 Nov;29(11):4337-43.

4.

The role of HIF1α in renal cell carcinoma tumorigenesis.

Gudas LJ, Fu L, Minton DR, Mongan NP, Nanus DM.

J Mol Med (Berl). 2014 Aug;92(8):825-36. doi: 10.1007/s00109-014-1180-z. Epub 2014 Jun 12. Review.

5.

Autophagy mediates HIF2α degradation and suppresses renal tumorigenesis.

Liu XD, Yao J, Tripathi DN, Ding Z, Xu Y, Sun M, Zhang J, Bai S, German P, Hoang A, Zhou L, Jonasch D, Zhang X, Conti CJ, Efstathiou E, Tannir NM, Eissa NT, Mills GB, Walker CL, Jonasch E.

Oncogene. 2015 May 7;34(19):2450-60. doi: 10.1038/onc.2014.199. Epub 2014 Jul 7.

6.

The von Hippel-Lindau tumor suppressor protein regulates gene expression and tumor growth through histone demethylase JARID1C.

Niu X, Zhang T, Liao L, Zhou L, Lindner DJ, Zhou M, Rini B, Yan Q, Yang H.

Oncogene. 2012 Feb 9;31(6):776-86. doi: 10.1038/onc.2011.266. Epub 2011 Jul 4.

7.

The protein tyrosine phosphatase receptor type J is regulated by the pVHL-HIF axis in clear cell renal cell carcinoma.

Casagrande S, Ruf M, Rechsteiner M, Morra L, Brun-Schmid S, von Teichman A, Krek W, Schraml P, Moch H.

J Pathol. 2013 Mar;229(4):525-34. doi: 10.1002/path.4107. Epub 2013 Jan 21.

PMID:
23007793
8.

Restricted expression of miR-30c-2-3p and miR-30a-3p in clear cell renal cell carcinomas enhances HIF2α activity.

Mathew LK, Lee SS, Skuli N, Rao S, Keith B, Nathanson KL, Lal P, Simon MC.

Cancer Discov. 2014 Jan;4(1):53-60. doi: 10.1158/2159-8290.CD-13-0291. Epub 2013 Nov 4.

9.

The molecular biology of renal cell carcinoma.

Keefe SM, Nathanson KL, Rathmell WK.

Semin Oncol. 2013 Aug;40(4):421-8. doi: 10.1053/j.seminoncol.2013.05.006. Review.

PMID:
23972705
10.

Loss of VHL and hypoxia provokes PAX2 up-regulation in clear cell renal cell carcinoma.

Luu VD, Boysen G, Struckmann K, Casagrande S, von Teichman A, Wild PJ, Sulser T, Schraml P, Moch H.

Clin Cancer Res. 2009 May 15;15(10):3297-304. doi: 10.1158/1078-0432.CCR-08-2779. Epub 2009 Apr 28.

11.

miR-30c-2-3p and miR-30a-3p: new pieces of the jigsaw puzzle in HIF2α regulation.

Moch H, Lukamowicz-Rajska M.

Cancer Discov. 2014 Jan;4(1):22-4. doi: 10.1158/2159-8290.CD-13-0897.

12.

Epigenetic regulation of HIF-1α in renal cancer cells involves HIF-1α/2α binding to a reverse hypoxia-response element.

Xu J, Wang B, Xu Y, Sun L, Tian W, Shukla D, Barod R, Grillari J, Grillari-Voglauer R, Maxwell PH, Esteban MA.

Oncogene. 2012 Feb 23;31(8):1065-72. doi: 10.1038/onc.2011.305. Epub 2011 Aug 15.

PMID:
21841824
13.

[The expression of hypoxia inducible factor-1,2 alpha in sporadic clear cell renal cell carcinoma and their relationships to the mutations of von Hippel-Lindau gene].

Gong K, Zhang N, Na X, Wu G, Yang XY, Xin DQ, Na YQ.

Zhonghua Wai Ke Za Zhi. 2005 Mar 15;43(6):390-3. Chinese.

PMID:
15854350
14.

Constitutive activation of hypoxia-inducible genes related to overexpression of hypoxia-inducible factor-1alpha in clear cell renal carcinomas.

Wiesener MS, Münchenhagen PM, Berger I, Morgan NV, Roigas J, Schwiertz A, Jürgensen JS, Gruber G, Maxwell PH, Löning SA, Frei U, Maher ER, Gröne HJ, Eckardt KU.

Cancer Res. 2001 Jul 1;61(13):5215-22.

15.

Chromosome 14q loss defines a molecular subtype of clear-cell renal cell carcinoma associated with poor prognosis.

Monzon FA, Alvarez K, Peterson L, Truong L, Amato RJ, Hernandez-McClain J, Tannir N, Parwani AV, Jonasch E.

Mod Pathol. 2011 Nov;24(11):1470-9. doi: 10.1038/modpathol.2011.107. Epub 2011 Jul 1.

17.

Interplay between pVHL and mTORC1 pathways in clear-cell renal cell carcinoma.

Kucejova B, Peña-Llopis S, Yamasaki T, Sivanand S, Tran TA, Alexander S, Wolff NC, Lotan Y, Xie XJ, Kabbani W, Kapur P, Brugarolas J.

Mol Cancer Res. 2011 Sep;9(9):1255-65. doi: 10.1158/1541-7786.MCR-11-0302. Epub 2011 Jul 28.

18.
19.

Genetic and functional studies implicate HIF1α as a 14q kidney cancer suppressor gene.

Shen C, Beroukhim R, Schumacher SE, Zhou J, Chang M, Signoretti S, Kaelin WG Jr.

Cancer Discov. 2011 Aug;1(3):222-35. doi: 10.1158/2159-8290.CD-11-0098. Epub 2011 Jun 7.

20.

Supplemental Content

Support Center